A Closer Look At OWC Pharmaceutical Research Corp (OTCMKTS:OWCP)

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has become one of the most talked about and active cannabis names. This comes as the company was trading at just $.0030 at the end of September before turning into a microcap runner and hitting highs of $.2150 on October 24. Now OWCP has pulled back and looks to be consolidating before making its next move higher. For those that haven't climbed on board yet, here's a closer look at OWCP.First up, a little background on the company. OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.In the middle of November, OWCP announced that it was submitting the final Psoriasis IRB safety protocol for the Israeli national IRB committee at the Health Minister office. The IRB protocol was first approved by the hospital which will perform the safety study and after obtaining its approval the IRB protocol is being submitted for approval to the national IRB committee. The national IRB committee is scheduled to ensemble at the beginning of December 2016. Upon the expected approval of the safety protocol by the national committee, the company will immediately engage with the study which will last approximately 12 weeks. Results are expected by the end of March 2016 and upon reaching satisfactory results the company intends to start production, marketing and sales in the US and EU in parallel to local IL efforts.The psoriasis topical crème infused with active cannabinoids is a unique delivery-system product of OWC designed to be used for skin diseases, where the first application will be tested for safety and efficacy for Psoriasis. The efficacy studies have already been started and results are expected by the end of Jan 2017. Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Dr. Yehuda Baruch said:

"Best to my knowledge this is the first Cannabis safety study that was submitted to the Israeli IRB national committee to be performed on healthy volunteers. I am also not aware of any other cannabis infused topical crème that was tested for safety, efficacy and bio-availability with approved IRB. That makes our products unique and valuable which matches exactly the company's vision and targets to develop approved, safe and effective active-cannabinoids products for medical treatments."

Besides the cream, OWCP has also completed the development of a proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis. The technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient’s blood through oral epithelial tissue. The Tablet also enables physicians to safely and accurately monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking.

OWCP is working towards having the Tablet approved by the Israeli Medicinal Cannabis Unit under the Ministry of Health office for use within the country’s sanctioned medical cannabis program, as well as talking with potential licensees of the technology in the United States. Longer term, management expects to establish clinical tests of the Tablet in protocols for Multiple Myeloma, Post-Traumatic Stress Disorder (PTSD), and Fibromyalgia.

Currently trading with a market cap of $14.8 million, OWCP is on the verge of some major developments. There are plenty of upcoming catalysts that will provide plenty of headlines for investors. We believe that new highs are still in store for OWCP and that any pullback represents a discount entry opportunity for long-term investors. We will be updating our subscribers as soon as we know more. For the latest updates on OWCP, sign up below!

Disclosure: We have no position in OWCP and have not been compensated for this article.